PAH drug missed its Phase 3 primary endpoint, yet FDA cleared an NDA filing path — approvability on borderline data is the only question that matters

Bull

FDA grants approval, accepting the totality of evidence including the near-miss primary endpoint (p=0.032 vs. threshold of 0.025), the highly significant NT-proBNP reduction (p=0.0002), and the pronounced effects in intermediate/high-risk and CTD-PAH subgroups as sufficient to establish a favorable benefit-risk profile. A positive outcome would validate the regulatory strategy and transform Gossamer from a development-stage company with a failed Phase 3 into a commercial-stage PAH franchise holder, with the reacquired worldwide rights from Chiesi/Roche maximizing the economic upside.

Bear

FDA concludes that the primary endpoint miss is disqualifying and that secondary endpoint data and subgroup analyses cannot compensate for the failure to achieve pre-specified statistical significance on the co-primary 6MWD measure, resulting in a Complete Response Letter. The most likely failure modes are an agency determination that the treatment effect magnitude (13.3m 6MWD improvement) is clinically insufficient, skepticism about the post-hoc subgroup analyses in CTD-PAH and intermediate/high-risk patients, and concern over the regional variability in placebo response that complicated the PROSERA dataset.